

Leading Innovations in Prevention and Cure

Donald D. Forrester, MD, CPE

In this article...

Discover the key concepts necessary to lead dramatic improvement in the care of chronic conditions, and read about one organization's success at controlling medical costs.

Medical organizations could and should be contributing to improving the health and sustainability of individuals, families, businesses, communities and governments. Their failure is reflected in the continual rise of health care costs along with the incidence of chronic diseases and the suffering and poor quality of life they beget. The situation is driving large nonmedical organizations to institute policies or programs to reduce their medical costs.

A common dilemma for leaders of medical organizations who wish to achieve breakthrough improvement is two-fold: how to proceed and where to obtain the necessary money. Money can be recovered by focusing on the treatment of chronic conditions that account for up to 75 percent of medical costs.¹

Success, however, requires a shift away from tertiary prevention (i.e., controlling complications with the use of drugs and procedures). Initially, the strategy involves a shift to secondary prevention (i.e., reversing and curing the conditions), and ultimately to primary prevention (i.e., preventing the condition from occurring). Success would be a marked reduction in the incidence of chronic disease and reduced costs.

To achieve dramatic results medical organizations will need to be led by effective teams. Their effectiveness will require best practices drawn from three areas:

- Clinical science
- Finance
- Innovation in complex systems

Clinical science

Leaders need to create environments that ensure that health care professionals have the skills and resources to identify and apply the best clinical science in caring for patients. This is challenging for three reasons. First, the number of biomedical and clinical articles published annually has risen from 200,000 in 1970 to more than 750,000 in 2010.²

Second, health care professionals focus on tertiary prevention and know very little about primary and secondary prevention, and are especially lacking in nutrition.

Finally, relevant information and skills needed for interpretation of clinical studies and quality improvement are not widely known and applied by health care professionals.

Finance

If money is to be recovered and health care costs reduced, it is important to use an effective finance model. This model needs to be based on an underlying principle of ecological economics that shifts the emphasis from growth to development.³ To support development, some of the profits of the innovation must be returned either directly or indirectly to the innovating clinical team as gain sharing. Figure 1 shows the conventional finance model as presented by Robert Kauer, MD.⁴

The boxes represent accounting values, and the arrows represent the key financial questions and flow of money in an organization. Question 4 is, "Of the profit, how much is going to dividend and how much is going to capital/innovation?" I have added gain sharing from profits as of the model.

Innovation in complex systems

Medical organizations and clinical teams are complex systems. They contain elements (i.e., both physical and nonphysical), interconnections (i.e., can be physical or information flows) and purpose (i.e., inferred from behavior and outcomes, not statements or rhetoric).

It is time for medical organizations to join Whole Foods Market in reducing the prevalence and incidence of chronic conditions, improving the health of their patients and employees, and reducing costs.

Complex systems are unpredictable, self-organizing and nonlinear. They create their own behavior, making them difficult to understand and control. However they can be redesigned and improved.⁶ The redesign process is best focused at the smallest functional unit in medical organizations, the clinical team.⁷

Innovation in complex systems is more effective if the appropriate interventions are employed. Donella Meadow's list of "Places to Intervene in a System" (Table 1, left column)⁸ is very useful when planning for breakthrough innovation. These levers of change range from the least (i.e., numbers) to the most effective (i.e., beliefs).

Successful innovation will align and properly use these levers (i.e., examples in medical organizations, right column). Two cautions: First, not everything that matters can be measured, and second it is necessary to monitor for unanticipated consequences. To avoid such consequences it is necessary to track results across all important areas.


Without thorough evaluation an intervention may optimize one-outcome while creating poor results in other areas. For example, access can be optimized while quality of care and/or staff satisfaction is compromised.

Chronic conditions: Type 2 diabetes

Diabetes costs about \$174 billion annually⁹ and affects an increasingly larger percentage of people in the United States. The



Fig. 1
Flow vs. Boxes



Gain-shared money should be used for "satisfiers" (i.e., training, improved service, work environment) and not "dissatisfiers" (i.e., salary, bonuses).⁵ The amount of money needs to be significant enough to obtain buy-in by members of the innovating clinical team and to support further development and profit.

Table 1

Numbers	Standards
Materials stocks and flows	Organizational structure
Regulating negative feedback loops	Prevention
Driving positive feedback loops	Growth
Information flows	Access to information
Rules of the system	Incentives, constraints
The power of self-organization	Innovation
The goals of the system	Profit, health of populations
The mindset, belief or paradigm	Cure of chronic disease

lifetime risk for people born in 2000 is estimated to be 33 percent for males and 38 percent for females.¹⁰

It accounts for 44 percent of new cases of kidney failure, 60 percent of nontraumatic lower-leg amputations, raises the risk of heart attack and stroke two to four times, and is the leading cause of blindness between age 20 and 74.

The current biomedical studies show that fats in the diet down-regulate genes controlling mitochondria¹¹ and increase insulin resistance.¹² Further, a low-fat plant-based diet leads to reduced intracellular fat and decreased insulin resistance.¹³

All cells in the body metabolize glucose (i.e., the bodies preferred fuel), whereas fructose, by contrast, is predominantly metabolized in the liver producing fatty acids, cholesterol and uric acid.¹⁴ Complex carbohydrates that are composed of long chains of glucose molecules, then, are not the cause of Type 2 diabetes.¹⁵

Understanding the science helps explain the clinical studies that support the use of a low-fat plant-based diet as superior to the American Diabetic Association diet that emphasizes reducing carbohydrates.^{16, 17} Coupling the best clinical science with successful approaches from the quality improvement literature is important.

Larry Staker, MD, at Intermountain Healthcare demonstrated that by changing the patient's display of daily fasting blood glucose data from tables to a specification chart, patients improved HgbA1C values on average by 0.5 percent.¹⁸ His specifications were chosen with a goal to "control" the patient's diabetes.

Given the more recent studies, and consistent with Meadow's levers of change, we can shift the patients' goal from "controlling" to "curing" Type 2 diabetes. The goal of curing diabetes (i.e., the normalization of glucose and the absence of medication) changes the approach from tertiary prevention to secondary prevention. To support this goal providers must be aware of the literature and accept the paradigm that it is possible to cure Type 2 diabetes.

In my clinical practice many patients with Type 2 diabetes cured their diabetes. Unfortunately the electronic health record in my clinic was incapable of registering this success (e.g., no diagnosis of s/p Type 2 diabetes). As such, an important feedback loop was absent.

And I was faced with a dilemma. I could continue to label cured patients as diabetic, which would partially but not entirely capture the success of the treatment pro-

gram, but not accurately reflect the patient's status. Or, I could remove the diagnosis altogether, accurately reflecting their status, but leaving the organization's "global percent control" lower than it should be.

One of the characteristics of change in complex systems is the production of unanticipated consequences. These clinical and nonclinical results can be either good or bad.

For instance, patients reversing and curing their Type 2 diabetes also lose weight, improve their blood pressure and lipids, and even reverse complications (e.g., diabetic neuropathy¹⁹ and microalbuminuria).²⁰ These results need to be tracked to give feedback to the patient to reinforce their and their health care provider's behavior. They are also important to demonstrate savings to the organization. These include short-term savings due to less medication, testing and visits, as well as long-term savings involving specialty consultations and treatments (e.g., dialysis, diabetic retinopathy and amputation).

Obesity

Obesity is a costly chronic condition affecting 35.7 percent of adults and 17 percent of youth.²¹ Medical costs are estimated at \$147 billion per year in 2008 dollars.²² Since the overweight condition is easy to self diagnose, patients are targets for direct marketing. In addition to medical costs, consumers pay substantial amounts for diet aids and services.

As with Type 2 diabetes, it is important to use correct measures and set appropriate goals. Medical organizations use the Body Mass Index (BMI) to diagnose patients as overweight, obese or extremely obese. Unfortunately the BMI has been shown to fail to accurately diagnose up to 50 percent of adult obesity.²³ In 1972, Ancel Keys who popularized what was originally the Quetelet Index²⁴ said the measure

should be used for populations and not individuals.²⁵ Given the limitations of the BMI measure, it is best to use an individual's weight to measure their progress and reserve BMI to track progress of populations.

With the high prevalence of obesity and its association with up to 18 comorbidities (e.g., diabetes, many cancers, arterial disease, osteoarthritis, asthma, gall bladder disease),²⁶ medical organizations have implemented secondary prevention programs. They often use focused approaches such as eliminating sugar and increasing exercise, or diets centering on calorie restriction or high-protein intake. These approaches are not supported in well-controlled studies.²⁷

Further, high-protein diets are by design high in cholesterol, saturated fat and dietary acids, and low in dietary fiber and carbohydrates leading to chronic conditions (e.g., arterial disease, renal insufficiency).²⁸ These poorly designed secondary prevention programs that require multiple visits and manufactured products are examples of waste.

Worse, many organizations and health care professionals are pursuing tertiary prevention with the active promotion of drugs or procedures such as gastric by-pass surgery. The number of these procedures has escalated from 14,000 in 1998²⁹ to 170,000 in 2005. The cost ranges from \$17,000 to \$26,000/case.³⁰ Studies are being done to expand the market (i.e., treat lower BMI's) and include recommendations for other conditions such as Type 2 diabetes. Although surgical treatment of obesity yields impressive short-term success, there are no long-term studies to show true costs, harms and benefits.

The science supports the prescription of diets that have low calorie density and that are eaten "ad libitum" (i.e. eat when hungry) as the most successful approach.³¹ We need to shift our treatment belief from reducing calories to reducing

the calorie density (i.e. calories/gram or calories/pound)³² of the foods we eat. This requires the elimination of animal products, refined oils and most processed carbohydrates.

The shift from the standard American diet to a low fat, plant-based diet is further supported by epidemiological studies that show that the BMI is lowest in those populations consuming the latter.³³

As with Type 2 diabetes it is important to set the proper goals (i.e., curing obesity, eliminating weight loss surgery), track improvement across other clinical areas (e.g., cholesterol, fasting blood sugar, blood pressure) and record financial outcomes (e.g., cost savings).

Arterial disease

Arterial disease covers a wide range of conditions amenable to primary and secondary prevention including coronary artery disease, hypertension,^{34,35,36} stroke,³⁷ aortic disease,³⁸ carotid disease,³⁹ peripheral vascular disease, back pain,⁴⁰ narrowed discs⁴¹ and sexual dysfunction in both males⁴² and females.⁴³ The treatment of coronary artery disease in the United States in 2006 consisted of 1.3 million angioplasties and 448,000 bypass surgeries at a cost of more than \$100 billion. Additionally, there were 27,000 deaths attributed to these procedures.

The primary and secondary prevention of arterial disease represents a significant opportunity for savings, improved care, and reduced morbidity and mortality. This high incidence and cost of arterial disease represents a significant opportunity for medical organizations to employ effective secondary prevention programs to avoid subsequent events.

Autopsy studies done on soldiers in Vietnam⁴⁴ and Korea⁴⁵ demonstrated that coronary artery disease is present early in life. The Pathobiological Determinants of Atherosclerosis in Youth study⁴⁶

showed that arterial disease is present by age 19 and has progressed to a significant degree by age 39. This high incidence, coupled with the silent nature of its progression, also makes arterial disease an ideal target for primary prevention programs.

Initially biomedical literature focused on cholesterol and the blockages within the arteries.⁴⁷ Early on we also began to understand the significance of diet.⁴⁸ It was puzzling that acute coronary events were not related to degree of stenosis and, in fact, generally occurred in arteries with less than 50 percent blockage.⁴⁹

The discovery of the nitrous oxide system by Robert Furchgott and others helped us understand the underlying mechanisms.⁵⁰ We are now better able to understand the success reported by Dean Ornish⁵¹ and Caldwell Esselstyn.⁵² They demonstrated improved symptoms, reversal of blockages and a marked reduction in subsequent events over years. A more recent study⁵³ demonstrated the improvement of symptoms within weeks. Exercise is helpful as well. This makes a strong case for shifting our focus from procedures that target discrete blockages to care that stabilizes the underlying disease.

The best science currently supports the prescription of a low-fat plant-based diet with Vitamin B12 supplementation.⁵⁴ Exercise should also be prescribed.⁵⁵ The prescription should include judicious use of medications. All demonstrated successful interventions (i.e. diet, exercise, medication) should be incorporated into a well-designed shared decision model for patients.^{56,57} Success in secondary prevention would be measured by decreased procedures (i.e., angioplasty, bypass surgeries) and decreasing recurrences and time to recurrence for coronary events. Primary prevention would be reflected in a decreased incidence of myocardial infarctions and strokes.

Health care professionals focus on tertiary prevention and know very little about primary and secondary prevention.

Steps to take

The first step is for health care leaders to design an innovative process based on the aforementioned concepts. Initially, a single functional primary care team should be selected to target Type 2 diabetes.

In my clinical experience the results with Type 2 diabetes are quickly apparent, as are short-term savings (e.g., visits, medications) and member satisfaction. There are also significant long-term savings (e.g., avoidance of referrals, treatment of eye, renal and arterial complications).

Further, the experience gained with successfully reversing and curing diabetes is easily translated to other chronic conditions often seen in primary care such as obesity and arterial disease, especially hypertension.

By starting with one clinical team, health care leaders can develop the financial and clinical models essential to demonstrate success and provide gain sharing with the alpha site. The accounting and finances will be challenging since the adoption of a science-based program for diabetes will also result in improvement in and/or avoidance of many chronic conditions (e.g., arterial disease, obesity, autoimmune disorders, certain cancers, osteoporosis).⁵⁸

After demonstrating success the process will more easily spread to beta sites in the same clinical specialty. A properly designed and implemented program will generate enough savings for gain sharing and funding additional projects in other

primary care specialties. The process can be extended to specialty departments to create a culture that is skilled in the primary and secondary prevention of chronic disease.

The next step would be considering adding a system that delivers on primary prevention. One highly successful well-documented program was the Multiphasic Testing Program developed by Morris Collen, MD, with Kaiser Permanente Medical Program in Oakland.

This two-visit program was available to all adult members every four years before age 50 and every two years after.⁵⁹ Whole Foods Market is demonstrating what is possible by implementing innovative programs targeting both primary and secondary prevention.

Success at Whole Foods Market

Whole Foods Market (WFM) is self-insured for medical costs. Between fiscal years 2005 and 2006 it experienced a 15.7 percent increase in medical costs as a percent of sales. In 2006 it added a health savings account to its benefit package. The increases for the next three years were 15.7 percent, 10.7 percent, and 13.3 percent.

In 2009 it introduced two policies that accelerated the reduction of medical costs as a percent of sales and improved the health of team members. The first is a voluntary biometric testing program for employees. All Whole Foods employ-

ees receive a 20 percent discount on purchases.

The biometric program consists of testing for weight, height (for BMI), blood pressure, and fasting cholesterol and glucose. Depending on the results, employees can be placed in the bronze, silver, gold or platinum health category, receiving discounts of 22.5 percent, 25 percent, 27.5 percent and 30 percent, respectively.

As of September 2011, 8,294 team members representing 12.9 percent of its almost 65,000 members had taken advantage of this policy. This represented almost \$2 million in additional savings for those members.

The second policy is to pay the transportation and attendance costs for team members in poor health to attend one of four residential eight-day immersion programs. WFM invests more than \$4,000/member to attend one of these programs. WFM requires interested team members to use their own leave and apply for consideration.

I have personally provided medical care to WFM team members at the McDougall Whole Foods program in Santa Rosa, CA. The immersion programs are modeled after the successful 10-day program by John McDougall, MD, and generate similar results.⁶⁰ The results in improved quality of life and decreased use of medication are remarkable.

Conversations with attendees attest to other benefits such as improved employee morale and decreased use of sick leave.

All three policies contributed to no increase in medical costs from 2009 to 2010 and a 10.4 percent decrease from 2010 to 2011, resulting in savings of \$10 million to \$20 million dollars.⁶¹

It is time for medical organizations to join Whole Foods Market in reducing the prevalence and incidence of chronic conditions, improving the health of their patients and employees, and reducing costs.

Health care leaders need to build work environments that support the development of sustainable high-performing clinical teams that deliver world-class service.⁶² Clinical teams properly supported can duplicate and build on the success of pioneering physicians such as McDougall.

Coupling clinical success in the exam room with supportive systems of care can help begin to reverse our bleak health care situation. I look forward to the first medical organization that is able to achieve a 50 percent reduction in the prevalence of an important chronic condition and lower health care costs. I believe it is achievable in the near future.



Donald D. Forrester, MD, CPE, conducts presentations for physicians and leadership teams. He lives in Sacramento, CA.
donforn@gmail.com

References:

1. Healthy Communities Preventing Chronic Disease by Activating Grassroots Change: At A Glance 2010, CDC Report Functional Unit reference
2. Institute of Medicine Best Care at Lower Cost: The Path to Continuously Learning Health Care in America, 2012.
3. Daly HE, *Beyond Growth*, p 13, Beacon Press, Boston, 1996.
4. Kauer R, The Institute for Advanced Study, Advanced Financial Analysis and Cost Management Seminar, American College of Physician Executives, Sept 1997.
5. Herzberg F, One More Time: How Do You Motivate Employees?, *Harvard Business Review*, Jan/Feb 1968.
6. Meadows DH, Dancing with Systems, *Whole Earth Magazine*, Winter 2001.
7. Nelson EC, Batalden PB, Huber TP, Mohr JJ, Godfrey MM, Headrick LA, and Wasson JH, Microsystems in Health Care: Part 1. Learning from High-Performing Front-line Clinical Units, *Journal of Quality Improvement*, 28(9):472-493. September 2002.
8. Meadows DH, Places to Intervene in a System, *Whole Earth Magazine*, Winter 1997.
9. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the US, 2011. Atlanta, GA: US Department of Health and Human Services Centers for Disease Control and Prevention, 2011.
10. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW and Williamson DF, Lifetime Risk for Diabetes Mellitus in the US, *JAMA*, 290(14): 1884-90, Oct. 8, 2003.
11. Sparks LM, Xie H, Koza RA, Mynatt R, Hulver MW, Bray GA and Smith SR, A High-Fat Diet Coordinately Downregulates Genes Required for Mitochondrial Oxidative Phosphorylation in Skeletal Muscle, *Diabetes*, 54(7), 1926-33, July 2005.
12. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI, Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes, *NEJM*, 350(7): 664-71, Feb. 12, 2004.
13. Goff LM, Bell JD, So P-W, Dornhorst A and Frost GS, Veganism and its relationship with insulin resistance and intramyocellular lipid, *European Journal of Clinical Nutrition*, 59; 291-298, Feb 2005.
14. Bray GA, How bad is fructose, *Am J Clin Nutr* 86:895-6, Oct. 2007.
15. Bessesen DH, The Role of Carbohydrates in Insulin Resistance, *J Nutr* 131:2782S-2786S, Oct. 1, 2001.
16. Barnard ND, Cohen J, Jenkins DJA, Turner-Grievy G, Gloede L, Jaster B, Seidl K, Green A and Talpers S, A Low-Fat Vegan Diet Improves Glycemic Control and Cardiovascular Risk Factors in a Randomized Clinical Trial in Individuals with Type 2 Diabetes, *Diabetes Care*, 29(8), Aug. 2006.
17. Barnard ND, Cohen J, Jenkins DJA, Turner-Grievy G, Gloede L, Green A and Ferdowsian H, A low-fat diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74-wk clinical trial, *Am J Clin Nutr*, 89(suppl): 1588S-96S, May 2009.
18. Staker, LV, Changing Clinical Practice by Improving Systems: The Pursuit of Clinical Excellence through Practice-Based Measurement for Learning and Improvement, *Quality Management in Health Care*, 9(1); 1-13, Fall 2000.
19. Crane, MG and Sample C, Regression of Diabetic Neuropathy with Total Vegetarian (Vegan) Diet, *J Nutritional Medicine*, 4: 431-439, 1994.
20. Jibani, MM *et al*, Predominantly Vegetarian Diet in Patients with Incipient and Early Clinical Diabetic Nephropathy: Effects on Albumin Excretion Rate and Nutritional Status, *Diabetic Medicine* 8 949-53, Dec. 1991.
21. Ogden CL, Carroll MD, Kit BK, and Flegl KM, Prevalence of Obesity in the United States, 2009-2010, US Dept HHS, CDC, NCHS Data Brief, 82, Jan 2012.
22. Finklestein EA, Trogon JG, Cohen JW and Dietz W, Annual Spending Attributable to Obesity: Payer and Service Specific Estimates, *Health Affairs*, 28(5), w822-w831, Sept. Oct. 2009.
23. Romero-Coral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J, Allison TG, Batsis JA, Sert-Kuniyoshi FH and Lopez-Jimenez F, Accuracy of body mass index in diagnosing obesity in the adult general population, *Int J Obes*, 32(6), 959-966, June 2008.
24. Eknoyan, E. Adolphe Quetelet – the average man and indices of obesity, *Nephrol Dial Transplant*, 23:47-51, 2008.
25. Keys A, Fidanza F, Karvonen MJ, Noboru, K and Taylor HL, Indices of Relative Weight and Obesity, *J Chron Dis*, 25(6-7); 329-343, July 1972.
26. Guh, DP, Zhang, W, Bansback, N, Amarsi, Z, Birmingham, CL, and Anis, AH, The incidence of co-morbidities related to obesity and overweight: A systemic review and meta-analysis, *BMC Public Health*, 9(88), 2009.
27. Tsai, AG and Wadden TA, Systematic Review: An Evaluation of Major Commercial Weight Loss Programs in the United States, *Ann Intern Med*, 142(1): 56-66, Jan. 4, 2005.
28. Knight EL, Stampfer MJ, Hankinson SE, Spiegelman D and Curhan GC, The Impact of Protein Intake on Renal Function Decline in Women with Normal Renal Function or Mild Renal Insufficiency, *Ann Int Med* 138(2003), 460-7, mar. 18, 2003.
29. Smoot TM, Xu P, Hilsenrath P, Kuppersmith NC and Singh DP, Gastric By Pass Surgery in United States, 1998-2002, *Am J Public Health*, 96(7):1187-89, July 2006.

30. Cremieux PY, Buchwald H, Shikora SA, Ghosh A, Yang HE and Buessign M, A Study on the Economic Impact of Bariatric Surgery, *Am J Managed Care* 14(9): 589-596, Sept. 2008.
31. Shintani TT, Beckham S, Brown AC and O'Connor HK, The Hawaii Diet: Ad Libitum High Carbohydrate, Low Fat Multi-cultural Diet for Reduction of Chronic Disease Risk Factors: Obesity, Hypertension, Hypercholesterolemia, and Hyperglycemia, *Hawaii Med J*, 60: 69-73, Mar. 2001.
32. Ledikwe JH, Blanck HM, Khan LK, Serdula MK, Seymour JD, Tohill BC and Rolls BJ, Dietary energy density is associated with energy intake and weight status in US Adults, *Am J Clin Nutr* 2006; 83:1362-8, June 8, 2006.
33. Tonstad S, Butler T, Yan R and Fraser GE, Type of vegetarian diet, body weight and prevalence of Type 2 Diabetes, *Diabetes Care*, 32(5): 791-6, May 2009.
34. Melby CL, Lyle RM, Poehlman ET. Blood pressure and body mass index in elderly long-term vegetarians and nonvegetarians. *Nutr Rep Int.* 37:47-55, 1988.
35. Margetts, BM *et al.*, A randomized control trial of a vegetarian diet in treatment of mild hypertension. *Clin Exp Pharmacolo Physiol.* 12:263-266, 1985.
36. Rouse IL *et al.*, Blood-pressure-lowering effect of a vegetarian diet: controlled trial in normotensive subjects. *Lancet.* 1: 5-10, Jan. 1, 1983.
37. E'lia L, Barba G, Cappuccio FP and Strazzulio P, Potassium intake, stroke, and cardiovascular disease a meta-analysis of prospective studies. *J Am Coll Cardiol.* 57(10):1210-9, Mar. 8, 2011.
38. Kent KC, Zwolak RM, Egorova NN, Riles TS, Manganaro A, Moskowitz AJ, Gelijns AC and Greco G, Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. *J Vasc Surg* 2010, Sep; 52(3): 539-48, Sept. 2010.
39. Le J, Zhang D, Menees S, Chen J and Raghuvveer G, "Vascular Age" is advanced in Children with Atherosclerosis Promoting Risk Factors, *Circ Cardiovasc Imaging*, published online Nov 17, 2009.
40. Kauppila LI, Mikkonen R, Mankinen P, Pelto-Vasenius K and Maenpaa I, MR Aortography and Serum Cholesterol Levels in Patients with Long-Term Nonspecific Lower Back Pain, *Spine*, 29(19):2147 - 52, Oct. 1, 2004.
41. Kauppila, LI, Penttila A, Karhunen PJ, Lalu K and Hannikainen P, Lumbar Disc Degeneration and Atherosclerosis of the Abdominal Aorta, *Spine*, 19(8): 923-29, Apr. 1994.
42. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM and Coltman CA, Erectile Dysfunction and Subsequent Cardiovascular Disease, *JAMA* 294(23):2996-3002, Dec. 21, 2005.
43. Esposito K, Ciotola M, Maiorino MI, Giugliano F, Autorino R, De Sio M, Cozzolino D, Saccomanno F and Giugliano D, Hyperlipidemia and sexual function in premenopausal women, *J Sex Med*, 6(6): 1696-703, June 2008.
44. McNamara JJ, Molot MA, Stremple JF and Cutting RT, Coronary Artery Disease in Combat Casualties in Vietnam, *JAMA*, 216(7): 1185-7, May 17, 1971.
45. Enos WF, Holmes RH and Beyer J, Coronary Disease among United States soldiers killed in action in Korea. *JAMA*, 152(12): 1090-1093, July 18, 1953.
46. Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP, Herderick EE and Cornhill JF, Prevalence and Extent of Atherosclerosis in Adolescents and Young Adults: Implications for Prevention From the Pathobiological Determinants of Atherosclerosis in Youth Study, *JAMA*, 281(8): 727-735, 1999.
47. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL and Steinberg D, Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids, *Proc Natl Acad Sci USA*, 81(12): 3883-7, June 1984.
48. Harrison DG, Armstrong ML, Freiman PC, Helstad DD, Restoration of Endothelium-dependent Relaxation by Dietary Treatment of Atherosclerosis, *J Clin Invest*, 80(6): 1808-1811, Dec. 1987.
49. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR and Santamore WP, Can coronary angiography predict the site of subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? *Circulation*, 78(5 Pt 1): 1157-66, 1988.
50. Furchgott, Robert F, Endothelium-Derived Relaxing Factor: Discovery, Early Studies, and Identification as Nitric Oxide, Nobel Lecture Dec 8, 1998. *Bioscience Reports*, 19(4):235-51, 1999.
51. Ornish D, Scherwitz LW, Billings JH, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C and Brand RJ, Intensive Lifestyle Changes for Reversal of Coronary Heart Disease, *JAMA*, 280(23): 2001-2007, Dec. 16, 1998.
52. Esselstyn CB, Ellis SG, Medendorp SV and Crowe TD, "A Strategy to Arrest and Reverse Coronary Artery Disease: A 5 year Longitudinal Study of a Single Physicians Practice," *J. Fam Pract*, 41(6); 560-568, Dec. 1995.
53. Frattaroli J, Weidner G, Merritt-Woods TA, Frenda S and Ornish D, Angina Pectoris and Atherosclerotic Risk Factors in the Multisite Cardiac Lifestyle Intervention Program. *Am J Cardio*, 101(7); 911-918, Apr. 1, 2008.
54. Esselstyn, CB, Resolving the Coronary Artery Disease Epidemic Through Plant-based Nutrition, *Preventive Cardiology* 4(4):171-7, Autumn 2007.
55. Green DJ, O'Driscoll G, Joyner MJ and Cable NT, Exercise and cardiovascular risk reduction: Time to update the rationale for exercise? *J Appl Physiol*, 105(2):766-8, Aug. 2008.
56. Dwamena F, Holmes-Rouner M, Gauden CM, Jorgenson S, Sadigh G, Sikorskii A, Lewin S, Smith RC, Coffey J and Olomu A, Interventions for providers to promote a patient-centred approach in clinical consultations, *Cochrane Database Syst Rev*, 2012 Dec 12;12CD003267. doi:10.1002/146518
57. Esselstyn CB, Is the Present Therapy for Coronary Artery Disease the Radical Mastectomy of the Twenty-First Century? *American J Cardiol*, doi: 10.1016/j.amjcard.2010.05.016.
58. Campbell TC and Campbell TM, *The China Study: the most comprehensive study of nutrition ever conducted and the startling implications for diet, weight loss, and long-term health*, Dallas Tx: BenBella Books, 2005.
59. Collen MF, *Multiphasic Health Testing Services*, Hoboken, NJ: John Wiley & Sons, 1978.
60. McDougall J, Litzau K, Haver E, Saunders V and Spiller GA, Rapid reduction of serum cholesterol and blood pressure by a twelve-day, very low-fat, strictly, vegetarian diet, *J Am College Nutrition*, 14(5):491-496, Oct. 1995.
61. Mackey J and Lederman M, Presentation: The Whole Story Whole Food Markets Healthy Eating Revolution, McDougall Advanced Study Weekend, February 19, 2012.
62. Forrester DD, A Path to World-Class Service for Medical Organizations, *Physicians Executive Journal*, Jul/Aug, 46-53, Jul-Aug 2011.